13G Filing: Great Point Partners and Catalyst Pharmaceuticals Inc. (CPRX)

Page 1 of 10

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX): Jeffrey Jay And David Kroin’s Great Point Partners filed an amended 13D.

You can check out Great Point Partners’ latest holdings and filings here.

Please follow Great Point Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Great Point Partners or update its stock holdings.

Follow Jeffrey Jay And David Kroin's Great Point Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Great Point Partners 0 5,262,346 0 5,262,346 5,262,346 5.14%
Dr. Jeffrey R. Jay, M.D 0 5,262,346 0 5,262,346 5,262,346 5.14%
Mr. David Kroin 0 5,262,346 0 5,262,346 5,262,346 5.14%

Follow Jeffrey Jay And David Kroin's Great Point Partners

Page 1 of 10 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

 

Under the Securities Exchange Act
of 1934

(Amendment No.  )*

 

Catalyst Pharmaceuticals, Inc.
(Name of Issuer)
Common
Stock
(Title of Class of Securities)
14888U101
(CUSIP Number)
November 28, 2017
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:

x Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)

*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Persons who respond to the collection of
information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Follow Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)












Page 1 of 10